Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed XXXX diagnoses?

@entity1 @entity303 @entity477 @entity1832 @entity5624 @entity179 @entity74 @entity195
BACKGROUND: @entity5624 and beta-amyloid ( @entity477 ) are proposed diagnostic biomarkers for @entity195 ( @entity195 ). Previous studies report their relationship to clinical diagnoses of @entity195 and other @entity303 . To understand their value as predictors of disease-specific pathology, levels determined during life must be correlated with definitive diagnoses in mixed @entity303 groups and cognitively normal subjects. OBJECTIVES: To correlate antemortem cerebrospinal fluid (CSF) tau and @entity477 levels with definitive @entity303 diagnosis in a diverse group of @entity1 ; to calculate statistics for CSF tau and @entity477 . DESIGN: Prospective study. SETTING: Ten clinics experienced in the diagnosis of @entity179 . @entity1 One hundred six @entity1 with @entity303 and 4 cognitively normal subjects with a definitive diagnosis, and 69 clinically diagnosed cognitively normal subjects. MAIN OUTCOME MEASURES: Correlation of CSF tau and @entity477 with final diagnosis. RESULTS: Mean tau level was 612 pg/mL for the 74 @entity1 with @entity195 , 272 pg/mL for 10 @entity1 with frontal @entity303 , 282 pg/mL for 3 @entity1 with @entity303 with @entity1832 , and 140 pg/mL for 73 cognitively normal control subjects. Tau was less than 334 pg/mL for 20 @entity1 with @entity195 . Abeta42 was reduced in @entity1 with @entity195 (61 fmol/mL) compared with @entity1 with frontal @entity303 (133 fmol/mL) and control subjects (109 fmol/mL), but not compared with @entity1 with @entity303 with @entity1832 (14 fmol/mL) or prion disease (60 fmol/mL). CONCLUSIONS: Elevated CSF tau levels are associated with @entity195 pathology and can help discriminate @entity195 from other @entity74 . However, some @entity1 with @entity195 have a level less than the mean +/- 2 SDs of the cognitively normal cohort.
